Crystalline pharmaceutically acceptable salt and polymorphic form of the glutaminyl cyclase inhibitor varoglutamstat
AssigneeVivoryon Therapeutics N.V.
InventorUlrich HEISER
Life of this patent
Estimating the term…
Abstract
The present invention is concerned with a crystalline pharmaceutically acceptable salt of the glutaminyl cyclase inhibitor Varoglutamstat. Varoglutamstat is chemically designated as (S)-1-(1H-benzo[d]imidazol-5-yl)-5-(4-propoxyphenyl)imidazolidin-2-one and is also known under the code PQ912. The invention further relates to a polymorphic form of the hydrochloride salt of (S)-1-(1H-benzo[d]imidazol-5-yl)-5-(4-propoxyphenyl)imidazolidin-2-one, to processes for preparing said hydrochloride salt and its polymorphic form, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing them.
Claims50
A polymorph of Varoglutamstat Hydrochloride which is characterized by X-ray powder diffraction peaks (2[Theta]) selected from one or more of the following:
- 9.5±0.2°, and 24.8±0.2°.
A process for preparing a hydrochloride salt of Varoglutamstat, said process comprising dissolving Varoglutamstat free base in a solvent mixture comprising a polar aprotic water-mixable organic solvent and water, adding a solution comprising HCl, and harvesting Varoglutamstat Hydrochloride crystals.
(canceled)
Dependencies are inferred from the claim text.